Contenuto

Informazioni per prime visite e consulenze specifiche della Struttura Complessa Ematologia

  1. Ruutu T, Corradini P, Gratwohl, Holler E, Apperley J, Dini G, Schmitz N, Sociè G, Niederwieser D. Use of intrathecal prophylaxis in allogeneic haematopoietic stem cell transplantation for malignant blood diseases: a survey of the European group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant, 2005, 35:121 – 124
  2. 2. Gahrton G, Iacobelli S, Apperley J, Bandini G, Bjorkstrand B, Bladè J, Cavo M, Cornelissen J, Corradini P, Kroeger N, Ljiungman P, Michallet M, Reiffers J, Russell NH, Samson D, Schattenberg A, Sirohi B, Verdonck LF, Volin L, Zander A, Niederwieser D. Donor gender impact on outcome in allogeneic hematopoietic stem cell transplantation for multiple myeloma reduced relapse risk in female to male transplants. Bone Marrow Transplant, 2005, 35: 1-9
  3. Vacca A, Scavelli C, Montefusco V, Di Pietro G, Neri A, Mattioli M, Bicciato S, nico B, Ribatti D, Dammacco F, Corradini P. Thalidomide down-regulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. Journal of Clinical Oncology 2005, 23:5334-46
  4. Dreger P, Brand R, Milligan D, Corradini P, Finke J, Lambertenghi Deliliers G, Martino R, Russell N, van Biezen A, Michallet M, Niederwieser D. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 2005, 19:1029-33
  5. Dodero A, Carrabba M, Milani R, Rizzo E, Raganato A, Montefusco V, Farina L, Milanesi M, Longoni P, Carlo Stella C, Corradini P. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. Exp Hematol 2005, 33:920-7
  6. Corradini P, Zallio F, Mariotti J, Farina L , Bregni M, Valagussa P, Ciceri F, Bacigalupo A, Dodero A, Lucesole M, Patriarca F, Rambaldi A, Scimè R, Locasciulli A, Bandini G, Gianni AM, Tarella C, Olivieri A . Effect of age and previous autologous transplantation on non-relapse mortalità and survival in 150 patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. Journal of Clinical Oncology 2005, 23:6690-8
  7. Peccatori J, Barkholt L, Demirer T, Soriani MP, Bruzzi P, Ciceri F, Zambelli A, Da Prada GA, Pedrazzoli P, Siena S, Massenkeil G, Martino R, Lenhoff S, Corradini P, Rosti G, Ringden O, Bregni M, Niederwieser D. Prognostic factors for survival in patients with advanced renal cell cancer undergoing non-myeloablative allogeneic stem cell transplantation. Cancer 2005, 104:2099-2103
  8. Poloni A, Balducci F , Pasquini R, Buscemi L, Tagliabracci L, Costantino E, Viola N, Corradini P, Masia MC, Leoni P, Olivieri A. Enfraftment capacity of bone marrow-derived mesenchymal cells following hematopoietic stem cell transplantation in patients receiving reduced intensity conditioning regimen. Leukemia 2006, 20: 329-335
  9. Bregni M, Fleischauer K, Bernardi M, Pescarollo A, Guggiari E, Lunghi F, Deola S, Scaramuzza S, Re F, Setola E, Monari M, Mazzi B, Servida P, Corradini P, Peccatori J. Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer. Bone Marrow Transplantation 2006, 37:311-315
  10. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, Carreras E, Devergie A, Guglielmi C, Kolb HJ, Niederwieser D. Allogeneic hematopietic stem cell transplantation for chronic myeloid leukemia in Europe 2006. Transplant activity, long term data and current results. Haematologica 2006, 91:513-521
  11. van de Donk NW, Kroger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MH, Nagler A, Verdonck LF, Lokhorst HM. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood. 2006 Apr 15
  12. Carlo-Stella C, Guidetti A, Di Nicola M, Longoni P, Cleris L, Lavazza C, Milanesi M, Milani R, Carrabba M, Farina L, Formelli F, Gianni AM, Corradini P. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice . Exp Hematol 2006, 34:721-727
  13. van de Donk NWCY, Kröger N, Hegenbart U, Corradini P, San Miguel J, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MHJ, Nagler A, Verdonck LF, Lokhorst HM . Prognostic factors for donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006, 37:1135-1141
  14. Bruno B, Patriarca F, Sorasio R, Mattei, D, Montefusco V, Peccatori J, Bonifazi F, Petrucci MT, Milone G, Guidi S, Giaccone L, Rotta M, Fanin R, Boccadoro M, Corradini P. Bortezomib with/without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica 2006, 91:837-839
  15. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, Gianni AM, Rambaldi A, Barbui T, Cortelazzo S. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous transplantation. Leukemia 2006, 20: 1533-1538
  16. Ladetto M, Vallet S, Benedetti F, Vitolo U, Martelli M, Callea V, Patti C, Coser P, Perrotti A, Sorio M, Boccomini C, Pulsoni A, Stelitano C, Scimè R, Boccadoro M, Rosato R, De Marco F, Zanni M, Corradini P, Tarella C. Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial. Leukemia 2006, 20:1840-1847
  17. Secondino S, Carrabba MG, Pedrazzoli P, Castagna L, Spina F, Grosso F, Bertuzzi A, Bay JO, Siena S, Corradini P, Niederwieser D, Demirer T. Reduced intensity stem cell transplantation for advanced soft tissue sarcoma in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation. Haematologica 2007, 92:418-420
  18. Majolino I, Davoli M, Carnevalli E, Locasciulli A, Di Bartolomeo P, Scimè R, Corradini P, Selleri C, Narni F, Musso M, Bregni M, Olivieri A, De Fabritiis P, Pogliani E, Duque arbelaez J, ruscio C, Bacigalupo A. Reduced intensity conditioning with thiotepa, fludarabine and melphalan is effective in advanced myeloma. Leukemia and Lymphoma 2007, 48: 759-766
  19. Bruno B, Sorasio R, Patriarca F, Montefusco V, Guidi S, Busca A, Scime R, Console G, Milone G, Marotta G, Dominietto A, Giaccone L, Rotta M, Falda M, Bacigalupo A, Bosi A, Corradini P, Fanin R, Pollichieni S, Boccadoro M; Gruppo Italiano Trapianto Midollo Osseo.Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma.Eur J Haematol. 2007 Apr;78(4):330-7.
  20. Ciceri F, Bonini C, Marktel S, Zappone E, Servida P, Bernardi M, Pescarollo A, Bondanza A, Peccatori J, Rossini S, Magnani Z, Salomoni M, Benati C, Ponzoni M, Callegaro L, Corradini P, Bregni M, Traversari C, Bordignon C. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation Blood. 2007 Jun 1;109(11):4698-707.
  21. Carlo-Stella C, Guidetti A, Di Nicola M, Lavazza C, Cleris L, Sia D, Longoni P, Milanesi M, Magni M, Nagy Z, Corradini P, Carbone A, Formelli F, Gianni AM.IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3.Cancer Res. 2007 Apr 1;67(7):3269-75
  22. Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, Zoli V, Fornari A, Novero D, Cabras A, Stella M, Comino A, Remotti D, Ponzoni M, Caracciolo D, Ladetto M, Magni M, Devizzi L, Rosato R, Boccadoro M, Bregni M, Corradini P, Gallamini A, Majolino I, Mirto S, Gianni AM. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia. 2007 Aug;21(8):1802-11.
  23. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R, Matteucci P, Bregni M, Scime R, Narni F, Pogliani E, Locasciulli A, Milani R, Carniti C, Bacigalupo A, Rambaldi A, Bonifazi F, Olivieri A, Gianni AM, Tarella C. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia. 2007 Nov;21(11):2316-23. Epub 2007 Jun 28
  24. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, Crippa C, Ciccone G, Omede P, Ambrosini MT, Gay F, Bringhen S, Musto P, Foa R, Knight R, Zeldis JB, Boccadoro M, Petrucci MT Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA Italian Multiple Myeloma Network. J Clin Oncol. 2007 Sep 4;
  25. Gahrton G, Iacobelli S, Bandini G, Björkstrand B, Corradini P, Crawley C, Hegenbart U, Morgan G, Kröger N, Schattenberg A, Schönland SO, Verdonck LF, Volin L, de Witte T, Niederwieser D; Myeloma Subcommittee of the EBMT. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. Haematologica. 2007 Nov;92(11):1513-8.
  26. Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota Scalabrini D, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an over-all survival advantage. Blood. 2008; 111:4004-4013
  27. Corradini P, Montefusco V. Does the addition of thalidomide to MP or low-intensity SCT improve survival in elderly multiple myeloma patients? Nat Clin Pract Oncol. 2008 May;5(5):254-5.
  28. Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, Pileri A, Boccadoro M, Ciceri F, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Passera R, Pizzolo G, Gianni AM, Rambaldi A. Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innnovative nei Linfomi Survey. J Clin Oncol. 2008; 26: 3166-3175
  29. Patriarca F, Petrucci MT, Bringhen S, Baldini L, Caravita T, Corradini P, Corso A, Di Raimondo F, Falcone A, Ferrara F, Morabito F, Musto P, Offidani M, Petrini M, Rizzi R, Semenzato G, Tosi P, Vacca A, Cavo M, Boccadoro M, Palumbo A. Considerations in the treatment of multiple myeloma: A consensus statement from Italian experts. Eur J Haematol. 2009 Feb;82(2):93-105. Epub 2008 Nov 6.
  30. Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, Farina L, Piva S, Palumbo A, Boccadoro M, Corradini P. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma. 2008 Nov;49(11):2156-62.
  31. Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M, Fanin R, Boccadoro M, Corradini P. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia. 2009 Feb 5. [Epub ahead of print]
  32. Dodero A, Carniti C, Raganato A, Vendramin A, Farina L, Spina F, Carlo-Stella C, Di Terlizzi S, Milanesi M, Longoni P, Gandola L, Lombardo C, Corradini P. Haploidentical stem cell transplantation following a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: post-transplant CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood. 2009 Feb 11. [Epub ahead of print]
  33. Bregni M, Bernardi M, Servida P, Pescarollo A, Crocchiolo R, Treppiedi E, Corradini P, Ciceri F, Peccatori J. Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. Bone Marrow Transplant. 2009 Feb 23. [Epub ahead of print]
  34. Farina L, Carniti C, Dodero A, Vendramin A, Raganato A, Spina F, Patriarca F, Narni F, Benedetti F, Olivieri A, Corradini P. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica. 2009 Apr 18. [Epub ahead of print]
Ultimo aggiornamento: mercoledì 16 maggio 2012

Menu di approfondimento

accedi al sito www.adobe.com per scaricare la versione freeware di Acrobat Reader

Per visualizzare documenti in formato PDF è necessario Adobe Reader ®.
Scarica la versione gratuita.